Article in Science signaling, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what money
Authors and funding
42 authors.
Diana Drago-GarciaDepartment of Immunology and Regenerative Biology, Weizmann Institute of Science, Rehovot 7610001, Israel.ORCID 0000-0001-6397-3123
Suvendu GiriDepartment of Immunology and Regenerative Biology, Weizmann Institute of Science, Rehovot 7610001, Israel.ORCID 0000-0002-7595-1359
Rishita ChatterjeeDepartment of Immunology and Regenerative Biology, Weizmann Institute of Science, Rehovot 7610001, Israel.
Arturo Simoni-NievesDepartment of Immunology and Regenerative Biology, Weizmann Institute of Science, Rehovot 7610001, Israel.ORCID 0000-0002-1353-260X
Maha AbedrabboDepartment of Immunology and Regenerative Biology, Weizmann Institute of Science, Rehovot 7610001, Israel.ORCID 0009-0005-5365-6497
Alessandro GennaDepartment of Immunology and Regenerative Biology, Weizmann Institute of Science, Rehovot 7610001, Israel.ORCID 0000-0003-4821-1491
Mary Luz Uribe RiosDepartment of Immunology and Regenerative Biology, Weizmann Institute of Science, Rehovot 7610001, Israel.ORCID 0000-0002-6567-2436
Moshit LindzenDepartment of Immunology and Regenerative Biology, Weizmann Institute of Science, Rehovot 7610001, Israel.
Arunachalam SekarDepartment of Immunology and Regenerative Biology, Weizmann Institute of Science, Rehovot 7610001, Israel.
Nitin GuptaDepartment of Immunology and Regenerative Biology, Weizmann Institute of Science, Rehovot 7610001, Israel.ORCID 0000-0001-6485-6113
Noa AharoniDepartment of Immunology and Regenerative Biology, Weizmann Institute of Science, Rehovot 7610001, Israel.
Tithi BhandariDepartment of Immunology and Regenerative Biology, Weizmann Institute of Science, Rehovot 7610001, Israel.ORCID 0009-0005-6610-7841
Agalyan MayalaguDepartment of Immunology and Regenerative Biology, Weizmann Institute of Science, Rehovot 7610001, Israel.ORCID 0009-0006-0886-4892
Luisa SchwarzmüllerDivision of Molecular Genome Analysis, German Cancer Research Center (DKFZ), Im Neuenheimer Feld 580, Heidelberg 69120, Germany.ORCID 0000-0002-7151-9913
Nooraldeen TaradeDivision of Molecular Genome Analysis, German Cancer Research Center (DKFZ), Im Neuenheimer Feld 580, Heidelberg 69120, Germany.ORCID 0000-0001-5301-6450
Rong ZhuMRC-Biostatistics Unit, University of Cambridge, Cambridge CB2 0SR, UK.ORCID 0000-0002-7758-4409
Harsha-Raj Mohan-RajuDepartment of Molecular Cell Biology, Weizmann Institute of Science, Rehovot, Israel.ORCID 0000-0002-4316-4959
Feride KaratekinDepartment of Immunology and Regenerative Biology, Weizmann Institute of Science, Rehovot 7610001, Israel.ORCID 0009-0009-5430-429X
Francesco RoncatoDepartment of Molecular Genetics, Weizmann Institute of Science, Rehovot 7610001, Israel.ORCID 0000-0002-3425-4135
Yaniv Eyal-LublingCancer Research UK Cambridge Institute, Department of Oncology, University of Cambridge and the Cambridge Cancer Centre, Cambridge CB2 0RE, UK.ORCID 0000-0003-3461-9621
Tal KeidarLautenberg Center for Immunology and Cancer Research, Institute for Medical Research Israel-Canada, Hebrew University-Hadassah Medical School, Jerusalem 91120, Israel.ORCID 0000-0003-1931-706X
Yam NofDepartment of Immunology and Regenerative Biology, Weizmann Institute of Science, Rehovot 7610001, Israel.
Nishanth Belugali NatarajDepartment of Immunology and Regenerative Biology, Weizmann Institute of Science, Rehovot 7610001, Israel.ORCID 0000-0003-2970-6739
Karin Shira BernshteinDepartment of Human Biology, University of Haifa, Haifa 3103301, Israel.ORCID 0009-0000-1836-5620
Bettina WagnerInstitute of in vivo and in vitro Models, University of Veterinary Medicine Vienna, Vienna 1210, Austria.ORCID 0009-0002-5335-2045
Nishanth Ulhas NairCancer Data Science Lab, National Cancer Institute, NIH, Bethesda, MD 20892, USA.ORCID 0000-0002-8832-0329
Neel SanghviCancer Data Science Lab, National Cancer Institute, NIH, Bethesda, MD 20892, USA.ORCID 0000-0003-2929-3401
Ronen AlonDepartment of Immunology and Regenerative Biology, Weizmann Institute of Science, Rehovot 7610001, Israel.ORCID 0000-0001-9161-6369
Rony SegerDepartment of Immunology and Regenerative Biology, Weizmann Institute of Science, Rehovot 7610001, Israel.ORCID 0000-0001-9363-8852
Eli PikarskyLautenberg Center for Immunology and Cancer Research, Institute for Medical Research Israel-Canada, Hebrew University-Hadassah Medical School, Jerusalem 91120, Israel.ORCID 0000-0003-4186-7105
Sara DonzelliOncogenomic and Epigenetic Unit, IRCCS Regina Elena National Cancer Institute, Rome 00144, Italy.ORCID 0000-0002-8529-2895
Giovanni BlandinoOncogenomic and Epigenetic Unit, IRCCS Regina Elena National Cancer Institute, Rome 00144, Italy.ORCID 0000-0002-6970-2241
Stefan WiemannDivision of Molecular Genome Analysis, German Cancer Research Center (DKFZ), Im Neuenheimer Feld 580, Heidelberg 69120, Germany.ORCID 0000-0003-4683-3174
Sima LevDepartment of Molecular Cell Biology, Weizmann Institute of Science, Rehovot, Israel.ORCID 0000-0002-2108-3330
Ron PrywesDepartment of Biological Sciences, Columbia University, New York, NY 10027, USA.ORCID 0009-0009-6617-1391
Dalit BarkanDepartment of Human Biology, University of Haifa, Haifa 3103301, Israel.ORCID 0000-0003-4714-0580
Oscar M RuedaMRC-Biostatistics Unit, University of Cambridge, Cambridge CB2 0SR, UK.ORCID 0000-0003-0008-4884
Carlos CaldasCancer Research UK Cambridge Institute, Department of Oncology, University of Cambridge and the Cambridge Cancer Centre, Cambridge CB2 0RE, UK.ORCID 0000-0003-3547-1489
Eytan RuppinCancer Data Science Lab, National Cancer Institute, NIH, Bethesda, MD 20892, USA.ORCID 0000-0002-7862-3940
Yosef ShilohDepartment of Human Molecular Genetics and Biochemistry, Tel Aviv University School of Medicine, Tel Aviv 6997801, Israel.ORCID 0000-0002-1538-6060
Maik DahlhoffInstitute of in vivo and in vitro Models, University of Veterinary Medicine Vienna, Vienna 1210, Austria.ORCID 0000-0001-9189-7631
Yosef YardenDepartment of Immunology and Regenerative Biology, Weizmann Institute of Science, Rehovot 7610001, Israel.ORCID 0000-0003-4168-7884
Funding
Intramural NIH HHS Z99 CA999999
6 · The paper itself
Abstract
Cellular plasticity mediates tissue development as well as cancer growth and progression. In breast cancer, a shift to a more epithelial phenotype (epithelialization) underlies a state of reversible cell growth arrest called tumor dormancy, which enables drug resistance, tumor recurrence, and metastasis. Here, we explored the mechanisms driving epithelialization and dormancy in aggressive mesenchymal-like breast cancer cells in three-dimensional cultures. Overexpressing either of the epithelial lineage-associated transcription factors OVOL1 or OVOL2 suppressed cell proliferation and migration and promoted transition to an epithelial morphology. The expression of
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.
Re-epithelialization of cancer cells increases autophagy and DNA damage: Implications for breast cancer dormancy and relapse. · full record | OpenQuestion